Q3 EPS Estimates for Vor Biopharma Lowered by HC Wainwright

Vor Biopharma Inc. (NASDAQ:VOR) – HC Wainwright lowered their Q3 2026 earnings estimates for shares of Vor Biopharma in a research note issued on Wednesday, August 12th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.91) per share for the quarter, down from their prior forecast of ($0.70). HC Wainwright currently has a “Buy” rating and a $31.00 target price on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($2.64) per share. HC Wainwright also issued estimates for Vor Biopharma’s Q4 2026 earnings at ($0.94) EPS, Q1 2027 earnings at ($0.74) EPS, Q2 2027 earnings at ($0.87) EPS, Q3 2027 earnings at ($0.89) EPS, Q4 2027 earnings at ($0.92) EPS, FY2027 earnings at ($3.65) EPS, FY2028 earnings at ($2.61) EPS and FY2029 earnings at $1.33 EPS.

A number of other equities analysts have also recently issued reports on VOR. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wedbush lifted their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Weiss Ratings raised shares of Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.38.

Vor Biopharma Trading Up 4.3%

Shares of Vor Biopharma stock opened at $23.29 on Friday. The company has a 50 day simple moving average of $18.36 and a two-hundred day simple moving average of $15.96. Vor Biopharma has a 1 year low of $6.50 and a 1 year high of $50.20.

Vor Biopharma (NASDAQ:VOR) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11).

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. increased its holdings in shares of Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after purchasing an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. grew its holdings in shares of Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Vor Biopharma in the fourth quarter worth $33,275,000. Paradigm Biocapital Advisors LP bought a new stake in Vor Biopharma in the fourth quarter worth $22,890,000. Finally, NEXTBio Capital Management LP purchased a new stake in Vor Biopharma during the fourth quarter valued at $13,080,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma News Roundup

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: Wedbush raised its price target for Vor Biopharma to $27 from $18, implying additional potential upside, although it maintained a Neutral rating. Wedbush Increases Vor Biopharma Price Target to $27
• Positive Sentiment: HC Wainwright reiterated its Buy rating and $31 price target. Its forecasts also continue to anticipate a shift to profitability, including projected positive EPS of $1.33 in fiscal 2029 and $3.89 in fiscal 2030.
• Neutral Sentiment: The revised HC Wainwright estimates provide investors with updated expectations for Vor Biopharma’s clinical-development spending and path toward profitability. The company is still expected to report substantial losses in the near term, including fiscal 2027 EPS of ($3.65) and fiscal 2028 EPS of ($2.61).
• Negative Sentiment: Vor Biopharma’s latest quarterly loss was $0.80 per share, worse than the $0.69 analyst consensus, reinforcing concerns about higher-than-expected expenses and near-term cash needs.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for Q3 2026 to ($0.91) from ($0.70) and Q4 2026 to ($0.94) from ($0.72). It also lowered fiscal 2027 EPS to ($3.65) from ($2.78), fiscal 2028 to ($2.61) from ($1.67), fiscal 2029 to $1.33 from $1.86, and fiscal 2030 to $3.89 from $4.27. These cuts suggest profitability may arrive later or be weaker than previously expected.
• Negative Sentiment: The shares decreased 6.5% after the weak earnings report, indicating that investors are focusing more on the earnings miss and downward estimate revisions than on the bullish price targets. Vor Biopharma Stock Price Down Following Weak Earnings

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).